Sign In
Buy CANF
$3.15
-0.130 (-3.96%)
At Close: Jul 31, 2026
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targ
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
07:47am, Tuesday, 17'th Mar 2026
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE Americ
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
10:21am, Thursday, 05'th Mar 2026
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
10:25am, Wednesday, 04'th Mar 2026
RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a biotechnology company advancing a pipeline of propriet
Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study
10:07am, Wednesday, 04'th Mar 2026
Can-Fite BioPharma Ltd. (AMEX: CANF) shares are up on Wednesday following the company's announcement that its drug, Namodenoson, successfully met the primary endpoint in a Phase 2a study for pretreate
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
07:00am, Wednesday, 04'th Mar 2026
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small mole
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
07:00am, Monday, 09'th Feb 2026
Namodenoson's oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
07:00am, Thursday, 05'th Feb 2026
Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: C
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
07:00am, Tuesday, 20'th Jan 2026
Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026 Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF)
Can-Fite BioPharma Stock Scheduled to Reverse Split on Monday, January 5th (NYSE:CANF)
01:20am, Sunday, 28'th Dec 2025
Can-Fite BioPharma Ltd. (NYSE: CANF)'s stock is scheduled to reverse split on the morning of Monday, January 5th. The 1-20 reverse split was recently announced. The number of shares owned by sharehold
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
04:46pm, Tuesday, 23'rd Dec 2025
RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs target
Can-Fite Provides Update on Clinical and Financial Status
09:19am, Tuesday, 16'th Dec 2025
RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs target
RAMAT GAN, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs target
Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
07:00am, Thursday, 20'th Nov 2025
~35% of erectile dysfunction patients in a $3.2 billion market are non-responders to brands including Viagra and Cialis, and these drugs can be contraindicated for an estimated 16 million men living w
Analyzing Can-Fite BioPharma (NYSE:CANF) & Generex Biotechnology (OTCMKTS:GNBT)
01:58am, Thursday, 23'rd Oct 2025
Generex Biotechnology (OTCMKTS:GNBT - Get Free Report) and Can-Fite BioPharma (NYSE: CANF - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the
